Rhea-AI Summary
Surface Oncology (Nasdaq: SURF) reported its Q1 2020 financial results and corporate milestones. Revenue surged to $38.6 million, up from $14.4 million in Q1 2019, driven by the completion of a collaboration with Novartis. R&D expenses decreased to $11.3 million from $14.3 million, while general and administrative expenses fell to $4.8 million. The company achieved significant clinical milestones, including the initiation of trials for SRF617 and SRF388. With cash and equivalents of $90.1 million, they are projected to fund operations into 2022.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.41%
Tags